EMVision Medical Devices (ASX:EMV) said that its first responder proof-of-concept device was tested in aeromedical retrieval environment settings, in collaboration with the Royal Flying Doctor Service and the Australian Stroke Alliance, according to a Wednesday Australian bourse filing.
The RFDS staff received preliminary training in the operation of the device with scans completed under an existing ethics approval. The device withstood the physical stress, environmental conditions, and operational constraints related to aeromedical retrieval.
It submitted an ethics application for the RFDS staff to enroll and scan patients in a usability and workflow implementation study set for the coming weeks.
The study will look at the device's usability, reliability, functionality, workflow metrics, among other tests.
Product development activities are underway to transition from advanced prototype proof-of-concept devices to production-equivalent commercial devices.
Another ethics application is underway for the use of the EMVision first responder scans during acute suspected stroke cases attended by the Melbourne Mobile Stroke Unit.
Its shares rose 5% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。